Baidu
map

Hypertension:糖尿病前期患者合并高血压时心血管意外风险会显著增大

2018-04-21 MedSci MedSci原创

糖尿病前期(Pre-DM)单独或合并高血压是否是心血管疾病的独立危险因素尚未完全明确。Hypertension杂志近期发表一篇相关文献。研究人员对Pre-DM与心血管疾病的关系是否与患者有无高血压而有所不同进行进一步探究。本研究共对7121例进行冠状动脉造影检查的心绞痛样胸痛患者进行评估,并招募了4193位冠状动脉造影确诊的稳定性、新发冠状动脉疾病患者。根据患者的糖尿病程度将其分为3组,并根据有无

糖尿病前期(Pre-DM)单独或合并高血压是否是心血管疾病的独立危险因素尚未完全明确。Hypertension杂志近期发表一篇相关文献。

研究人员对Pre-DM与心血管疾病的关系是否与患者有无高血压而有所不同进行进一步探究。本研究共对7121例进行冠状动脉造影检查的心绞痛样胸痛患者进行评估,并招募了4193位冠状动脉造影确诊的稳定性、新发冠状动脉疾病患者。根据患者的糖尿病程度将其分为3组,并根据有无高血压进一步分层。

通过病变血管的数量和Gensini评分评估冠状动脉疾病的严重程度。对所有研究对象进行规律随访,以获得复合终点的发生情况。

平均随访11338个患者年,共发生434例(10.35%)心血管事件。Pre-DM组和血糖控制正常组之间冠脉病变程度和复合终点未观察到显著差异(p>0.05)。但是,将高血压纳入分层因素时,Pre-DM合并高血压和DM合并高血压组的心血管疾病风险(以冠脉严重程度和临床诊断评估)明显增加(p<0.05)。

本研究结果表明对于稳定性、新发冠状动脉疾病患者,Pre-DM患者心血管疾病风险增高主要是由于合并高血压,而不是Pre-DM本身引起。

原始出处:

Hui-Hui Liu,et al.Impacts of Prediabetes Mellitus Alone or Plus Hypertension on the Coronary Severity and Cardiovascular Outcomes.Hypertension. April 18,2018.https://doi.org/10.1161/HYPERTENSIONAHA.118.11063

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2038887, encodeId=c86e203888e2e, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Apr 25 02:07:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727254, encodeId=d25f1e27254dd, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Feb 01 08:07:00 CST 2019, time=2019-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501281, encodeId=88fb15012817a, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Mon Apr 23 06:07:00 CST 2018, time=2018-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307940, encodeId=473830e94064, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40ad2312069, createdName=1222becem95暂无昵称, createdTime=Sat Apr 21 15:42:42 CST 2018, time=2018-04-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2038887, encodeId=c86e203888e2e, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Apr 25 02:07:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727254, encodeId=d25f1e27254dd, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Feb 01 08:07:00 CST 2019, time=2019-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501281, encodeId=88fb15012817a, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Mon Apr 23 06:07:00 CST 2018, time=2018-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307940, encodeId=473830e94064, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40ad2312069, createdName=1222becem95暂无昵称, createdTime=Sat Apr 21 15:42:42 CST 2018, time=2018-04-21, status=1, ipAttribution=)]
    2019-02-01 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=2038887, encodeId=c86e203888e2e, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Apr 25 02:07:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727254, encodeId=d25f1e27254dd, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Feb 01 08:07:00 CST 2019, time=2019-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501281, encodeId=88fb15012817a, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Mon Apr 23 06:07:00 CST 2018, time=2018-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307940, encodeId=473830e94064, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40ad2312069, createdName=1222becem95暂无昵称, createdTime=Sat Apr 21 15:42:42 CST 2018, time=2018-04-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2038887, encodeId=c86e203888e2e, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Apr 25 02:07:00 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727254, encodeId=d25f1e27254dd, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Feb 01 08:07:00 CST 2019, time=2019-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501281, encodeId=88fb15012817a, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Mon Apr 23 06:07:00 CST 2018, time=2018-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=307940, encodeId=473830e94064, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40ad2312069, createdName=1222becem95暂无昵称, createdTime=Sat Apr 21 15:42:42 CST 2018, time=2018-04-21, status=1, ipAttribution=)]
    2018-04-21 1222becem95暂无昵称

    学习了

    0

相关资讯

J Hypertens:糖尿病前期交感神经和压力反射异常!

由此可见,这些数据提供了交感神经反射异常发生在糖尿病发病早期的证据。因此,肾上腺素能过度兴奋和压力反射受损可能参与疾病进展,其有利于高血压的发展并对疾病预后产生不利影响。

Clin Gastroenterol Hepatol:相比糖尿病前期患者,吡格列酮显著降低了2型糖尿病患者肝纤维化,并增加了脂肪组织胰岛素敏感性

在本项前瞻性研究中,发现吡格列酮对2型糖尿病患者有效。相比糖尿病前期患者,吡格列酮显著降低了2型糖尿病患者肝纤维化,并增加了脂肪组织胰岛素敏感性。

JAMA:近4成中国成人处于糖尿病前期 令人担忧!

中国有世界上最大的糖尿病人群,并且在不断的增加。1980年和2010年报道的中国糖尿病的患病率分别为0.67%和11.6%。根据2010年的调查显示,糖尿病前期的患病率为50.1%。2013年研究者在中国大陆开展了一项全国代表性横断面调查,提供最新的糖尿病和糖尿病前期流行率数据,调查结果2017年6月发表在了《JAMA》。请看本期多学科讨论组临床药师各抒己见为您梳理本文看点——

JCEM:HbA1c“火眼金睛”识别糖尿病前期和亚临床心脏改变患者

大家都知道糖尿病前期与发展至心力衰竭的亚临床心脏改变有关,2017年8月1日在JCEM上发表的一篇文章研究了在糖尿病前期患者中舒张功能与糖基化及心血管相关疾病炎症标志物的关系。

JCEM:体力活动一定可以改善糖尿病前期患者血糖状况?那可说不准

大家都知道体力活动(PA)对于糖尿病患者的益处,但是你知道PA对于由OGTT或HbA1c诊断的糖尿病前期患者的血糖改善有不同影响么?

Am J Clin Nutr:补充镁可降低胰岛素抵抗、糖尿病前期或非传染性慢性疾病患者血压

补充镁元素对人体的健康有重大意义。2017年9月,发表在《Am J Clin Nutr》上的一项研究调查了补充镁对胰岛素抵抗、糖尿病前期或非传染性慢性疾病患者的血压(BP)影响。结果表明,补充镁显着降低胰岛素抵抗、糖尿病前期或其他非传染性慢性疾病患者的BP。

Baidu
map
Baidu
map
Baidu
map